Your browser doesn't support javascript.
Anticoagulantes orales directos: puesta al día. / Anticoagulantes orales directos: puesta al día. / Direct oral anticoagulants: An update.
Med Clin (Barc) ; 151(5): 198-206, 2018 09 14.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29295790
Vitamin K antagonists were the only choice for chronic oral anticoagulation for more than half a century. Over the past few years, direct oral anticoagulants have emerged, including one direct thrombin inhibitor (dabigatran etexilate) and three factor Xa inhibitors (apixaban, edoxaban and rivaroxaban). In randomised controlled trials comparing direct oral anticoagulants with traditional vitamin K antagonists, the direct oral anticoagulants all showed a favourable benefit-risk balance in their safety and efficacy profile, in prevention of thromboembolic events in patients with atrial fibrillation and in the prevention and treatment of venous thromboembolism and acute coronary syndrome. In 2008, dabigatran was the first direct oral anticoagulant approved by the European Medicine Agency. Subsequently, rivaroxaban, apixaban and edoxaban were also authorised. This article reviews the evidence related to the use of these drugs.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Antitrombinas / Acidente Vascular Cerebral Aspecto clínico: Etiologia / Terapia Limite: Humanos Idioma: Inglês / Espanhol Revista: Med Clin (Barc) Ano de publicação: 2018 Tipo de documento: Artigo